Skip to main content
. Author manuscript; available in PMC: 2020 Mar 20.
Published in final edited form as: Sci Transl Med. 2019 Aug 14;11(505):eaav6419. doi: 10.1126/scitranslmed.aav6419

Fig. 5. Model-predicted vaccine effectiveness and impact of an additional dose of rotavirus vaccine administered at 9 months of age.

Fig. 5.

(A) Predicted vaccine effectiveness over two years of follow-up (January 2018 to December 2019) is plotted for infants 4 to 11 months of age and 12 to 23 months of age for the four different models. (B-E) The predicted number of rotavirus-associated gastroenteritis (RVGE) cases presenting to QECH per year for 2011 to 2020 is plotted by age and for all children <5 years of age for the current vaccine schedule (solid lines) and the model including an additional dose at 9 months of age (dashed lines) for (B) Model 1, (C) Model 2, (D) Model 3, and (E) Model 4. The ‘x’s indicate the observed annual number of RVGE cases at QECH in 2012 to 2016. (F) The predicted overall effect (reduction in the relative incidence of RVGE) for the models including an additional dose of vaccine at 9 months of age versus the current vaccine schedule for the 3-year period from January 2018 to December 2020 by age and for all children <5 years old.